EGFR and non-small cell lung carcinoma: In this study (WJOG8815L/LPS), conducted as an exploratory biomarker study, we evaluated the usefulness of longitudinal monitoring of ctDNA in EGFR T790M mutation‐positive NSCLC patients receiving treatment with osimertinib.